Table 2.
Relationship between malignant neoplasms and the presence of metabolic syndrome components in HBV-infected patients.
| Cancer Site | MS(+) (n = 582,449) |
MS(−) (n = 922,431) |
||||
|---|---|---|---|---|---|---|
| Case, No. | Incidence Rate No./1000 PYs |
Case, No. | Incidence Rate No./1000 PYs |
Adjusted HR | p-Value | |
| Overall cancer | 40,628 | 14.21 | 57,167 | 12.20 | 1.17 (1.15–1.18) | <0.0001 |
| HCC | 10,156 | 3.57 | 19,256 | 4.02 | 0.86 (0.84–0.88) | <0.0001 |
| Biliary | 1312 | 0.44 | 1489 | 0.31 | 1.45 (1.35–1.56) | <0.0001 |
| Stomach | 5022 | 1.71 | 5638 | 1.17 | 1.46 (1.41–1.52) | <0.0001 |
| Colorectum | 4260 | 1.45 | 4473 | 0.93 | 1.56 (1.50–1.63) | <0.0001 |
| Esophagus | 634 | 0.21 | 783 | 0.16 | 1.33 (1.20–1.48) | <0.0001 |
| Pancreas | 1468 | 0.50 | 1408 | 0.29 | 1.72 (1.60–1.85) | <0.0001 |
| lung | 4260 | 1.44 | 4937 | 1.02 | 1.42 (1.36–1.48) | <0.0001 |
| Renal | 1072 | 0.36 | 943 | 0.20 | 1.87 (1.71–2.04) | <0.0001 |
| thyroid | 2985 | 1.01 | 4744 | 0.98 | 1.03 (0.98–1.08) | 0.29 |
| Laryngeal | 333 | 0.11 | 369 | 0.08 | 1.48 (1.28–1.71) | <0.0001 |
| Oral | 614 | 0.21 | 845 | 0.17 | 1.19 (1.07–1.32) | 0.001 |
| Lymphoma | 826 | 0.28 | 1158 | 0.24 | 1.17 (1.07–1.28) | 0.006 |
| Leukemia | 443 | 0.15 | 530 | 0.11 | 1.38 (1.21–1.56) | <0.0001 |
| Skin | 140 | 0.05 | 168 | 0.03 | 1.38 (1.10–1.72) | 0.005 |
| Nerves | 432 | 0.15 | 559 | 0.12 | 1.27 (1.12–1.44) | 0.0002 |
| Male | ||||||
| Prostate | 2785 | 1.58 | 2911 | 1.12 | 1.43 (1.36–1.50) | <0.0001 |
| Testicular | 30 | 0.02 | 33 | 0.01 | 1.34 (0.82–2.20) | 0.24 |
| Female | ||||||
| Breast | 1717 | 1.45 | 2215 | 1.43 | 1.01 (0.95–1.08) | 0.67 |
| Corpus | 286 | 0.24 | 489 | 0.22 | 1.10 (0.95–1.28) | 0.19 |
| Ovarian | 254 | 0.21 | 458 | 0.21 | 1.04 (0.89–1.22) | 0.59 |
| Cervical | 257 | 0.22 | 456 | 0.20 | 1.06 (0.91–1.23) | 0.47 |
MS, Metabolic syndrome; HR, hazard ratio; HCC, hepatocellular carcinoma.